TRIP10

Across TCGA pan-cancer cohorts, TRIP10 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of TRIP10’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TRIP10 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types TRIP10 is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, CCRCC, and LUAD are the cancer types where TRIP10 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRIP10 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	−0.780	<.001	12	view →
CCRCC	Male	All	+0.319	<.001	11	view →
LUAD	Female	II,III,IV	−0.356	<.001	9	view →
LSCC	All	All	−0.403	<.001	8	view →
COAD	Male	II,III,IV	−0.164	<.001	8	view →
PDAC	Male	All	+0.414	<.001	6	view →
OV	All	All	−0.295	.021	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

TRIP10–HNSC

Open the HNSC breakdown →